Vanzacaftor + Deutivacaftor + Tezacaftor
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Vanzacaftor + Deutivacaftor + Tezacaftor in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Vanzacaftor + Deutivacaftor + Tezacaftor.
36
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Vanzacaftor + Deutivacaftor + Tezacaftor
The rare inherited disease affects approximately 11,000 people in the UK
The rare inherited disease affects more than 109,000 people worldwide
Over 11,000 people in the UK are affected by the rare genetic disease
The company compared the treatment to its current triple cystic fibrosis therapy
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology